The Food and Drug Administration on Jan. 31, 2020 approved Palforzia, Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for peanut allergy… Read more »
Tag: AR101
Panel Backs FDA Approval for Aimmune’s Peanut OIT Drug
An expert advisory panel has recommended that the Food and Drug Administration approve Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for… Read more »
Longer Trial Increased Level of Tolerance to AR101 Peanut Therapy
By extending the peanut biologic oral immunotherapy known as AR101 by 28 weeks, a new study finds that a majority… Read more »
NEJM Publishes Positive Study Data on OIT Biologic for Peanut Allergy
The positive results of a pivotal Phase 3 study of a peanut biologic oral immunotherapy known as AR101 were published… Read more »
Peanut OIT Therapy Sees Success, Boosting Hope for FDA Approval
An FDA-approved treatment for food allergy is closer to reality after Aimmune Therapeutics announced that its large, Phase 3 trial… Read more »
FDA Labels Peanut OIT Treatment “Breakthrough Therapy”
All of the participants in the Phase II trial were able to tolerate nearly 2 peanut kernels at the end of two months.